Imperagen Secures £5 Million Seed Funding to Transform Enzyme Engineering with Quantum Physics and AI

TL;DR

• Imperagen has raised £5 million in a seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.
• The Manchester-based biotech uses quantum physics simulations, custom AI models, and automated lab testing to speed up enzyme engineering.
• The new funding will support R&D, lab expansion, hiring, and commercialization efforts across pharma, life sciences, and industrial biotech.

Manchester spin-out Imperagen has secured £5 million in fresh seed funding as it looks to accelerate enzyme engineering with an unusual combination of quantum physics, artificial intelligence, and automated laboratory experimentation.

The round was led by PXN Ventures, with ongoing support from existing backers IQ Capital and Northern Gritstone. The company says the new capital will help it expand its research team, grow lab capacity, and push its technology closer to commercial deployment.

A New Approach to Enzyme Design

Imperagen is tackling one of biotechnology’s long-standing bottlenecks: designing enzymes quickly and accurately. Traditional enzyme engineering often depends on iterative trial-and-error testing in the lab, which can be slow, expensive, and difficult to scale.

The Manchester-based company says its platform replaces much of that guesswork with a closed-loop system that combines three core elements: quantum physics-based simulation, custom AI models, and robotic lab automation. Together, those tools are used to predict how enzyme variants will behave, test the most promising candidates, and feed the results back into the system for the next design cycle.

According to the company, that approach allows it to evaluate millions of mutations computationally and improve enzyme performance in a fraction of the time required by conventional methods.

Five Development Cycles, 500x Improvement

Imperagen says its platform has already delivered striking results, with enzyme performance improving by more than 500 times in just five development cycles.

That kind of progress is notable in an industry where improvements are often incremental and require extensive lab work. By combining simulation, machine learning, and high-throughput experimentation, the company claims it can dramatically shorten the path from concept to validated enzyme.

The broader goal is to produce better enzymes faster and at lower cost, making them more practical for real-world use in a range of industries.

Where the Technology Could Be Used

Imperagen is targeting applications across pharmaceuticals, life sciences, personal care, sustainable fine chemicals, and industrial biotechnology.

Enzymes are already important in manufacturing and research, but better-designed enzymes can improve reaction efficiency, reduce waste, lower energy consumption, and enable more sustainable production processes. That makes them valuable not just for drug development, but also for food, materials, and specialty chemical manufacturing.

By focusing on speed and precision, Imperagen is positioning itself as a platform company that could serve multiple sectors rather than a single narrow vertical.

Why Investors Are Paying Attention

The funding round reflects growing investor interest in “techbio” companies that sit at the intersection of biology, software, and advanced computation.

Imperagen’s mix of quantum physics, AI, and robotics gives it a differentiated pitch in a crowded biotech landscape. Rather than relying solely on lab throughput or model-driven design, the company integrates both into a closed loop, where each experiment improves the next prediction.

For investors, that can translate into a more scalable and defensible engine for discovering and optimizing enzymes, especially if the platform continues to show strong performance gains in real-world use.

What the Funding Will Support

Imperagen says the new funds will be used to advance core research and development, expand its experimental lab capabilities, and hire additional AI talent. The company also plans to build out its go-to-market function over the next couple of years as it works to convert customer interest into revenue.

That suggests a shift from proving the technical concept to turning the platform into a commercial business. As with many deeptech and biotech startups, the next phase will likely be just as important as the science itself.

A Broader Signal for Biotech Innovation

Imperagen’s raise highlights a broader trend in biotech: the increasing use of computation and automation to reshape how biological products are discovered and optimized.

Quantum-inspired simulation, AI-driven prediction, and robot-assisted experimentation are becoming more central to how startups approach complex biological problems. In enzyme engineering, where large search spaces and costly experiments have long slowed progress, that convergence could be especially powerful.

Imperagen is betting that the future of enzyme design will be less about manual iteration and more about intelligent systems that can learn, test, and improve continuously.

If the company can sustain its early performance gains and translate them into commercial partnerships, this latest funding round could mark an important step toward a more automated era of industrial biotechnology.

AndroGuider Team

Articles written by the AndroGuider team. We try to make them thorough and informational while being easy to read.